Total Payments
$24,175
2024 Payments
$10,029
Companies
6
Transactions
25
Medicare Patients
977
Medicare Billing
$255,021
Payment Breakdown by Category
Travel$12,248 (50.7%)
Consulting$7,670 (31.7%)
Other$3,140 (13.0%)
Food & Beverage$1,072 (4.4%)
Research$44.40 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $12,248 | 13 | 50.7% |
| Consulting Fee | $7,670 | 2 | 31.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,140 | 1 | 13.0% |
| Food and Beverage | $1,072 | 7 | 4.4% |
| Unspecified | $44.40 | 2 | 0.2% |
Payments by Type
General
$24,130
23 transactions
Research
$44.40
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $11,611 | 7 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $8,642 | 10 | $0 (2019) |
| Ascendis Pharma Inc | $3,781 | 4 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $75.00 | 1 | $0 (2018) |
| Plexxikon Inc. | $44.40 | 2 | $0 (2018) |
| Incyte Corporation | $21.49 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,029 | 4 | F. Hoffmann-La Roche AG ($10,029) |
| 2023 | $3,781 | 4 | Ascendis Pharma Inc ($3,781) |
| 2019 | $10,224 | 13 | Regeneron Pharmaceuticals, Inc. ($8,642) |
| 2018 | $116.89 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($75.00) |
| 2017 | $24.00 | 1 | Plexxikon Inc. ($24.00) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/23/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $8,748.83 | General |
| 04/23/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $845.34 | General |
| 04/23/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $279.46 | General |
| 04/23/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $155.62 | General |
| 06/19/2023 | Ascendis Pharma Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,140.00 | General |
| 06/19/2023 | Ascendis Pharma Inc | — | Travel and Lodging | Cash or cash equivalent | $378.73 | General |
| 06/01/2023 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 06/01/2023 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $112.34 | General |
| 06/19/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $5,310.00 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,360.00 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $49.11 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $194.00 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $175.17 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $147.00 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $169.78 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $166.40 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $35.25 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $35.25 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $1,016.64 | General |
| Category: None | ||||||
| 03/13/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $306.50 | General |
| Category: None | ||||||
| 03/13/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $258.48 | General |
| Category: None | ||||||
| 07/21/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 03/20/2018 | Plexxikon Inc. | — | — | In-kind items and services | $20.40 | Research |
| Study: PLX120-03 | ||||||
| 01/26/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.49 | General |
| Category: Hematology/Oncology | ||||||
| 06/03/2017 | Plexxikon Inc. | — | — | In-kind items and services | $24.00 | Research |
| Study: PLX120-03 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PLX120-03 | Plexxikon Inc. | $44.40 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 276 | 594 | $462,952 | $73,376 |
| 2022 | 3 | 235 | 499 | $386,983 | $61,532 |
| 2021 | 3 | 217 | 572 | $437,832 | $71,783 |
| 2020 | 5 | 249 | 561 | $390,043 | $48,331 |
Total Patients
977
Total Services
2,226
Medicare Billing
$255,021
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 159 | 471 | $364,083 | $58,566 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 65 | 65 | $70,525 | $9,989 | 14.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 39 | 45 | $25,965 | $3,684 | 14.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 13 | 13 | $2,379 | $1,137 | 47.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 132 | 381 | $294,513 | $47,768 | 16.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 48 | 48 | $52,080 | $7,831 | 15.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 55 | 70 | $40,390 | $5,932 | 14.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 131 | 467 | $360,991 | $60,313 | 16.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 54 | 73 | $42,121 | $6,148 | 14.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 32 | 32 | $34,720 | $5,322 | 15.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 111 | 310 | $239,630 | $29,770 | 12.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 75 | 176 | $101,552 | $12,164 | 12.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $16,275 | $2,286 | 14.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 19 | 19 | $16,473 | $2,216 | 13.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 29 | 41 | $16,113 | $1,895 | 11.8% |
About Dr. Alain Algazi, M.D
Dr. Alain Algazi, M.D is a Hematology & Oncology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1821289794.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alain Algazi, M.D has received a total of $24,175 in payments from pharmaceutical and medical device companies, with $10,029 received in 2024. These payments were reported across 25 transactions from 6 companies. The most common payment nature is "Travel and Lodging" ($12,248).
As a Medicare-enrolled provider, Algazi has provided services to 977 Medicare beneficiaries, totaling 2,226 services with total Medicare billing of $255,021. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location San Francisco, CA
- Active Since 08/06/2007
- Last Updated 08/06/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1821289794
Products in Payments
- LIBTAYO (Biological) $8,642
- Non-Covered Product (Drug) $1,582
- NINLARO (Drug) $75.00
- JAKAFI (Drug) $21.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Francisco
Dr. Terence Friedlander, Ms, MS
Hematology & Oncology — Payments: $248,592
Hematology & Oncology $248,592
Pamela Munster, Md, MD
Hematology & Oncology — Payments: $98,260
Hematology & Oncology $98,260
Dr. Caroline Behler, M.d., M.s, M.D., M.S
Hematology & Oncology — Payments: $64,653
Hematology & Oncology $64,653
David Oh
Hematology & Oncology — Payments: $57,997
Hematology & Oncology $57,997
Dr. Paul Volberding, Md, MD
Hematology & Oncology — Payments: $51,997
Hematology & Oncology $51,997
Rebecca Olin, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579